Bacterial/Permeability-Increasing Protein, Human Neutrophil (BPI, CAP57)

PRODUCT NUMBER:

MW: 55,000
Extinction Coefficient: 1.0

Frozen in 80 mM Citrate Phosphate, pH 5.6, 700-750 mM NaCl.

Storage: <= -70°C

Bacterial/Permeability-Increasing Protein (BPI) is present in the azurophilic granules of polymorphonuclear leukocytes (PMN). BPI is toxic only toward Gram-negative bacteria. This specificity is attributable to the strong attraction of BPI for the lipopolysaccharides (LPS) in the bacterial envelope. BPI is also an important antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in vasculitis.

Purity: >=95% by SDS-PAGE

Prepared from whole blood shown to be non reactive for HBsAg, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA-required tests.

Athens Research & Technology products are laboratory reagents and are not to be administered to humans or used for any drug purpose. For research or further manufacturing use only.

Product Citation:

Zhao M.H., Jones S.J., and Lockwood C.M.. Clin Exp Immunol 1995. 99, 49. Elsbach P., and Weiss J. Immunobiology 1993. 187, 417.

Budding, K., E. A. van de Graaf, T. Hoefnagel, C. E. Hack, and H. G. Otten. "Anti-BPIFA1/SPLUNC1: A new autoantibody prevalent in patients with endstage cystic fibrosis." Journal of Cystic Fibrosis (2013).

Baron, Olga Lucia, Pieter van West, Benoit Industri, Michel Ponchet, Géraldine Dubreuil, Benjamin Gourbal, Jean-Marc Reichhart, and Christine Coustau. "Parental Transfer of the Antimicrobial Protein LBP/BPI Protects Biomphalaria glabrata Eggs against Oomycete Infections." PLoS Pathogens 9, no. 12 (2013): e1003792.

Skopelja S, Hamilton BJ, Jones JD, Yang ML, Mamula M, Ashare A, Gifford AH, Rigby WF.
The role for neutrophil extracellular traps in cystic fibrosis autoimmunity.
JCI Insight. 2016 Oct 20;1(17):e88912.